MicroRNA‑217 is involved in the progression of atherosclerosis through regulating inflammatory responses by targeting sirtuin 1

Zhang,Liyun; Chen,Juan; He,Qin; Chao,Ze; Li,Xuyong; Chen,Manhua

doi:10.3892/mmr.2019.10581

MicroRNA‑217 is involved in the progression of atherosclerosis through regulating inflammatory responses by targeting sirtuin 1

Authors:
- Liyun Zhang
- Juan Chen
- Qin He
- Ze Chao
- Xuyong Li
- Manhua Chen
View Affiliations

Affiliations: Department of Cardiology, Wuhan Central Hospital, Wuhan, Hubei 430015, P.R. China
Published online on: August 9, 2019 https://doi.org/10.3892/mmr.2019.10581
Pages: 3182-3190
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Atherosclerosis is a chronic inflammatory disease, and it is a global clinical problem. The development of new and effective therapeutic targets for atherosclerosis is necessary. A number of microRNAs (miRNAs) have been demonstrated to serve a crucial role in atherosclerosis. However, the role of miRNA (miR)‑217 in atherosclerosis remains unclear. Therefore, the aim of the present study was to investigate the role and mechanism of miR‑217 in atherosclerosis. The level of miR‑217 was detected in the blood of patients with atherosclerosis using reverse transcription‑quantitative PCR. THP‑1 acute monocytic leukemia cells were treated with oxidized low‑density lipoprotein (ox‑LDL) to develop an atherosclerotic cell model of macrophages. The relationship between miR‑217 and sirtuin 1 (SIRT1) was determined by TargetScan and dual luciferase reporter assay. Cell apoptosis was measured by flow cytometry. Production of pro‑inflammatory factors and triglyceride (TG) and total cholesterol (TC) levels were also determined. The results demonstrated that miR‑217 was significantly upregulated in atherosclerosis. SIRT1 was demonstrated to be a direct target of miR‑217 and was downregulated in atherosclerosis. Downregulation of miR‑217 significantly inhibited ox‑LDL‑induced TG and TC level increase, cell apoptosis and the upregulation of the pro‑inflammatory factors tumor necrosis factor α, interleukin (IL)‑6 and IL‑1β. Additionally, the SIRT1/AMP‑activated protein kinase α/NF‑κB pathway was at least partially involved in modulating the effects of miR‑217 inhibition on THP‑1 cells treated with ox‑LDL. In addition, the effects of miR‑217 downregulation on ox‑LDL‑treated THP‑1 cells were eliminated by SIRT1 silencing. In conclusion, the results of the present study indicated that miR‑217 downregulation may relieve atherosclerosis through the inhibition of macrophage apoptosis and inflammatory response by targeting SIRT1.

View Figures

View References

1	Libby P and Theroux P: Pathophysiology of coronary artery disease. Circulation. 111:3481–3488. 2005. View Article : Google Scholar : PubMed/NCBI
2	Williams KJ and Tabas I: Atherosclerosis and inflammation. Science. 297:521–522. 2002. View Article : Google Scholar : PubMed/NCBI
3	Ross R: Atherosclerosis-an inflammatory disease. N Engl J Med. 340:115–126. 1999. View Article : Google Scholar : PubMed/NCBI
4	Tabas I: Macrophage death and defective inflammation resolution in atherosclerosis. Nat Rev Immunol. 10:36–46. 2010. View Article : Google Scholar : PubMed/NCBI
5	Hansson GK and Libby P: The immune response in atherosclerosis: A double-edged sword. Nat Rev Immunol. 6:508–519. 2006. View Article : Google Scholar : PubMed/NCBI
6	Hansson GK and Hermansson A: The immune system in atherosclerosis. Nat Immunol. 12:204–212. 2011. View Article : Google Scholar : PubMed/NCBI
7	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
8	Hammond SM: An overview of microRNAs. Adv Drug Deliv Rev. 87:3–14. 2015. View Article : Google Scholar : PubMed/NCBI
9	Ghildiyal M and Zamore PD: Small silencing RNAs: An expanding universe. Nat Rev Genet. 10:94–108. 2009. View Article : Google Scholar : PubMed/NCBI
10	Soifer HS, Rossi JJ and Saetrom P: MicroRNAs in disease and potential therapeutic applications. Mol Ther. 15:2070–2079. 2017. View Article : Google Scholar
11	Krol J, Loedige I and Filipowicz W: The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 11:597–610. 2010. View Article : Google Scholar : PubMed/NCBI
12	O'Connell RM, Rao DS, Chaudhuri AA and Baltimore D: Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol. 10:111–122. 2010. View Article : Google Scholar : PubMed/NCBI
13	Mendell JT and Olson EN: MicroRNAs in stress signaling and human disease. Cell. 148:1172–1187. 2012. View Article : Google Scholar : PubMed/NCBI
14	Hosin AA, Prasad A, Viiri LE, Davies AH and Shalhoub J: MicroRNAs in atherosclerosis. J Vasc Res. 51:338–3349. 2014. View Article : Google Scholar : PubMed/NCBI
15	Wang LP, Wang JP and Wang XP: HOTAIR contributes to the growth of liver cancer via targeting miR-217. Oncol Lett. 15:7963–7972. 2018.PubMed/NCBI
16	Safaralizadeh R, Ajami N, Nemati M, Hosseinpourfeizi M, Azimzadeh Isfanjani A and Moaddab SY: Dysregulation of miR-216a and miR-217 in gastric cancer and their clinical significance. J Gastrointest Cancer. 50:78–83. 2019. View Article : Google Scholar : PubMed/NCBI
17	Liu AN, Qu HJ, Yu CY and Sun P: Knockdown of LINC01614 inhibits lung adenocarcinoma cell progression by upregulating miR-217 and downregulating FOXP1. J Cell Mol Med. 22:4034–4044. 2018. View Article : Google Scholar : PubMed/NCBI
18	Yan J, Wu G, Chen J, Xiong L, Chen G and Li P: Downregulated miR-217 expression predicts a poor outcome in acute myeloid leukemia. Cancer Biomark. 22:73–78. 2018. View Article : Google Scholar : PubMed/NCBI
19	Liu H, Li X, Song Y and Wang Z: MicroRNA-217 attenuates intima-media complex thickness of ascending aorta measured by ultrasound bio-microscopy and inhibits inflammation and lipid metabolism in atherosclerotic models of ApoE^−/− mice. Lipids Health Dis. 17:1702018. View Article : Google Scholar : PubMed/NCBI
20	Liu K, Xuekelati S, Zhou K, Yan Z, Yang X, Inayat A, Wu J and Guo X: Expression profiles of six atherosclerosis-associated microRNAs that cluster in patients with hyperhomocysteinemia: A clinical study. DNA Cell Biol. 37:189–198. 2018. View Article : Google Scholar : PubMed/NCBI
21	Nogueiras R, Habegger KM, Chaudhary N, Finan B, Banks AS, Dietrich MO, Horvath TL, Sinclair DA, Pfluger PT and Tschöp MH: Sirtuin 1 and sirtuin 3: Physiological modulators of metabolism. Physiol Rev. 92:1479–1514. 2012. View Article : Google Scholar : PubMed/NCBI
22	da Cunha MSB and Arruda SF: Tucum-do-Cerrado (Bactris setosa Mart.) may promote anti-aging effect by upregulating SIRT1-Nrf2 pathway and attenuating oxidative stress and inflammation. Nutrients. 9(pii): E12432017. View Article : Google Scholar : PubMed/NCBI
23	Rada P, Pardo V, Mobasher MA, García-Martínez I, Ruiz L, González-Rodríguez Á, Sanchez-Ramos C, Muntané J, Alemany S, James LP, et al: SIRT1 controls acetaminophen hepatotoxicity by modulating inflammation and oxidative stress. Antioxid Redox Signal. 28:1187–1208. 2018. View Article : Google Scholar : PubMed/NCBI
24	Chan SH, Hung CH, Shih JY, Chu PM, Cheng YH, Lin HC and Tsai KL: SIRT1 inhibition causes oxidative stress and inflammation in patients with coronary artery disease. Redox Biol. 13:301–309. 2017. View Article : Google Scholar : PubMed/NCBI
25	Cheng YY, Kao CL, Ma HI, Hung CH, Wang CT, Liu DH, Chen PY and Tsai KL: SIRT1-related inhibition of pro-inflammatory responses and oxidative stress are involved in the mechanism of nonspecific low back pain relief after exercise through modulation of Toll-like receptor 4. J Biochem. 158:299–308. 2015. View Article : Google Scholar : PubMed/NCBI
26	Yang X, Wei J, He Y, Jing T, Li Y, Xiao Y, Wang B, Wang W, Zhang J and Lin R: SIRT1 inhibition promotes atherosclerosis through impaired autophagy. Oncotarget. 8:51447–51461. 2017.PubMed/NCBI
27	Ross R: Atherosclerosis-an inflammatory disease. N Engl J Med. 340:115–126. 1999. View Article : Google Scholar : PubMed/NCBI
28	Nagy L, Tontonoz P, Alvarez JG, Chen H and Evans RM: Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell. 93:229–240. 1998. View Article : Google Scholar : PubMed/NCBI
29	Han Y, Ma J, Wang J and Wang L: Silencing of H19 inhibits the adipogenesis and inflammation response in ox-LDL-treatedRaw264.7 cells by up-regulating miR-130b. Mol Immunol. 93:107–114. 2018. View Article : Google Scholar : PubMed/NCBI
30	Tsui L and Wang IJ: Analysis and quantification of oxidized low-density lipoprotein-induced lipid droplets in macrophages through high-content screening: Application for antiatherogenic drugs discovery. Assay Drug Dev Technol. 17:223–230. 2019. View Article : Google Scholar : PubMed/NCBI
31	Du XJ, Lu JM and Sha Y: MiR-181a inhibits vascular inflammation induced by ox-LDL via targeting TLR4 in human macrophages. J Cell Physiol. 233:6996–7003. 2018. View Article : Google Scholar : PubMed/NCBI
32	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
33	Herrington W, Lacey B, Sherliker P, Armitage J and Lewington S: Epidemiology of atherosclerosis and the potential to reduce the global burden of atherothrombotic disease. Circ Res. 118:535–546. 2016. View Article : Google Scholar : PubMed/NCBI
34	Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 352:1685–1695. 2005. View Article : Google Scholar : PubMed/NCBI
35	Ryo A, Suizu F, Yoshida Y, Perrem K, Liou YC, Wulf G, Rottapel R, Yamaoka S and Lu KP: Regulation of NF-kappaB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Mol Cell. 12:1413–1426. 2003. View Article : Google Scholar : PubMed/NCBI
36	Imanishi T and Akasaka T: Novel strategies to target inflammatory processes in atherosclerosis. Curr Pharm Design. 19:1616–1625. 2013. View Article : Google Scholar
37	Li P, Zhong X, Li J, Liu H, Ma X, He R and Zhao Y: MicroRNA-30c-5p inhibits NLRP3 inflammasome-mediated endothelial cell pyroptosis through FOXO3 down-regulation in atherosclerosis. Biochem Biophys Res Commun. 503:2833–2844. 2018. View Article : Google Scholar : PubMed/NCBI
38	Wei Y, Nazari-Jahantigh M, Chan L, Zhu M, Heyll K, Corbalán-Campos J, Hartmann P, Thiemann A, Weber C and Schober A: The microRNA-342-5p fosters inflammatory macrophage activation through an Akt1- and microRNA-155-dependent pathway during atherosclerosis. Circulation. 127:1609–1619. 2013. View Article : Google Scholar : PubMed/NCBI
39	Zernecke A, Bidzhekov K, Noels H, Shagdarsuren E, Gan L, Denecke B, Hristov M, Köppel T, Jahantigh MN, Lutgens E, et al: Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal. 2:ra812009. View Article : Google Scholar : PubMed/NCBI
40	Zhang Y, Liu D, Chen X, Li J, Li L, Bian Z, Sun F, Lu J, Yin Y, Cai X, et al: Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol Cell. 39:133–144. 2010. View Article : Google Scholar : PubMed/NCBI
41	Nazari-Jahantigh M, Wei Y, Noels H, Akhtar S, Zhou Z, Koenen RR, Heyll K, Gremse F, Kiessling F, Grommes J, et al: MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in macrophages. J Clin Invest. 122:4190–4202. 2012. View Article : Google Scholar : PubMed/NCBI
42	Qin B, Shu Y, Long L, Li H, Men X, Feng L, Yang H and Lu Z: MicroRNA-142-3p induces atherosclerosis-associated endothelial cell apoptosis by directly targeting rictor. Cell Physiol Biochem. 47:1589–1603. 2018. View Article : Google Scholar : PubMed/NCBI
43	Wu Y, Xin D, Liu C and Wang F: SIRT1 participates in epithelial-mesenchymal transition of EC-9706 and Eca-109 cells in vitro by regulating Snail expression. Nan Fang Yi Ke Da Xue Xue Bao. 38:1325–1330. 2018.(In Chinese). PubMed/NCBI
44	Tian Y, Ma J, Wang W, Zhang L, Xu J, Wang K and Li D: Resveratrol supplement inhibited the NF-κB inflammation pathway through activating AMPKα-SIRT1 pathway in mice with fatty liver. Mol Cell Biochem. 422:75–84. 2016. View Article : Google Scholar : PubMed/NCBI
45	Jung CH, Lee MJ, Kang YM, Lee YL, Seol SM, Yoon HK, Kang SW, Lee WJ and Park JY: C1q/TNF-related protein-9 inhibits cytokine-induced vascular inflammation and leukocyte adhesiveness via AMP-activated protein kinase activation in endothelial cells. Mol Cell Endocrinol. 419:235–243. 2016. View Article : Google Scholar : PubMed/NCBI
46	Zabielska MA, Borkowski T, Slominska EM and Smolenski RT: Inhibition of AMP deaminase as therapeutic target in cardiovascular pathology. Pharmacol Rep. 67:682–688. 2015. View Article : Google Scholar : PubMed/NCBI